{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T19:38:31Z","timestamp":1782243511674,"version":"3.54.5"},"reference-count":22,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Chemotherapy"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1179\/joc.2005.17.1.46","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T13:05:31Z","timestamp":1389272731000},"page":"46-53","source":"Crossref","is-referenced-by-count":13,"title":["<i>In Vitro<\/i>\n                    Synergy and Selection of Resistance by Fluoroquinolones Plus Amikacin or \u03b2-Lactams Against Extended-Spectrum \u03b2-Lactamase-Producing\n                    <i>Escherichia coli<\/i>"],"prefix":"10.1080","volume":"17","author":[{"given":"L.","family":"Drago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"De Vecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Legnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Gismondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2013,11,20]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s100960100455"},{"key":"e_1_2_1_3_1","first-page":"708","article-title":"The MYSTIC Study Group (Europe)","volume":"9","author":"Jones RN","year":"2003","unstructured":"Jones RN, Pfaller MA, The MYSTIC Study Group (Europe). Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. Clin Microbiol Infect 2003; 9: 708\u2013712.","journal-title":"Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. Clin Microbiol Infect"},{"key":"e_1_2_1_4_1","first-page":"3506","volume":"47","author":"Arpin C","year":"2003","unstructured":"Arpin C, Dubois V, Coulange L et al. Extended spec-trum beta-lactamase-producing Enterobacteriaceae in commu-nity and private health care centers. Antimicrob Agents Chemother 2003; 47: 3506\u20133514.","journal-title":"Extended spec-trum beta-lactamase-producing Enterobacteriaceae in commu-nity and private health care centers. Antimicrob Agents Chemother"},{"key":"e_1_2_1_5_1","article-title":"Dell'Amico E","volume":"41","author":"Pagani L","year":"2003","unstructured":"Pagani L, Dell'Amico E, Migliavacca R. Multiple CTX-M-Type extended -spectrum 13-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in Northern Italy. J Clin Microbiol 2003; 41: 4264-4269.","journal-title":"Migliavacca R. Multiple CTX-M-Type extended -spectrum 13-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in Northern Italy."},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00497-6"},{"key":"e_1_2_1_7_1","doi-asserted-by":"crossref","unstructured":"Winkour PI Canton R Casellas R Casellas JM Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characteri-zation of isolates from Europe the Americas and the Western Pacific region. Clin Infect Dis 2001: 32 (suppl 2): S94-103.","DOI":"10.1086\/320182"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.00723.x"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2003.07.003"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.1.2.139"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000069786"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00317-4"},{"key":"e_1_2_1_13_1","first-page":"43","article-title":"Activities of cli-nafloxacin alone and in combination with other compounds, against 45 Gram-positive and -negative organisms for which clinafloxacin MICs are high","volume":"1999","author":"Clark CL","unstructured":"Clark CL, Jacobs MR, Appelbaum PC. Activities of cli-nafloxacin alone and in combination with other compounds, against 45 Gram-positive and -negative organisms for which clinafloxacin MICs are high. Antimicrob Agents Chemother 1999; 43: 2295-2298.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_14_1","first-page":"94","article-title":"Garcia de Lomas J","volume":"44","author":"Gimeno C","year":"1998","unstructured":"Gimeno C, Borja J, Navarro D, Valdes L, Gracia-Barbal J, Garcia de Lomas J. In vitro interaction between ofloxacin and cefotaxime against Gram-positive and Gram-negative bac-teria involved in serious infections. Chemotherapy 1998; 44: 94\u201398.","journal-title":"In vitro interaction between ofloxacin and cefotaxime against Gram-positive and Gram-negative bac-teria involved in serious infections. Chemotherapy"},{"key":"e_1_2_1_15_1","doi-asserted-by":"crossref","unstructured":"Mich\u00eaa Hamzehpour M Kahr A Pech\u00e8re JC. In vitro stepwise selection of resistance to quinolones I3-lactams and amikacin in nosocomial Gram-negative bacilli. Infection 1994; 22 (suppl 2): S105-110.","DOI":"10.1007\/BF01793574"},{"key":"e_1_2_1_16_1","unstructured":"National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Eleventh Informational Supplement M 100-S 11. Villanova NCCLS 2001."},{"key":"e_1_2_1_17_1","unstructured":"European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID): EUCAST Definitive Document E. Def 1.2. Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect 2000; 6: 503-508."},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.1073"},{"key":"e_1_2_1_19_1","first-page":"655","volume":"38","author":"Lautenbach E","year":"2004","unstructured":"Lautenbach E, Strom BL, Nachamkin I et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004; 38: 655\u2013662.","journal-title":"Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis"},{"key":"e_1_2_1_20_1","first-page":"196","volume":"21","author":"Molstad S","year":"2003","unstructured":"Molstad S. Reduction in antibiotic prescribing for respi-ratory tract infections is needed! Scan J Prim Health Care 2003; 21: 196\u2013198.","journal-title":"Reduction in antibiotic prescribing for respi-ratory tract infections is needed! Scan J Prim Health Care"},{"key":"e_1_2_1_21_1","first-page":"182","article-title":"Association of antibiotic utilization measures and reduced incidence of infec-tions with extended-spectrum beta-lactamase-producing organ-isms","volume":"36","author":"Lan CK","year":"2003","unstructured":"Lan CK, Hsueh PR, Wong WW et al. Association of antibiotic utilization measures and reduced incidence of infec-tions with extended-spectrum beta-lactamase-producing organ-isms. J Microbiol Immunol Infect 2003; 36: 182\u2013186.","journal-title":"J Microbiol Immunol Infect"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02561666"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.1.55"}],"container-title":["Journal of Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1179\/joc.2005.17.1.46","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T09:30:07Z","timestamp":1770370207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1179\/joc.2005.17.1.46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["10.1179\/joc.2005.17.1.46"],"URL":"https:\/\/doi.org\/10.1179\/joc.2005.17.1.46","relation":{},"ISSN":["1120-009X","1973-9478"],"issn-type":[{"value":"1120-009X","type":"print"},{"value":"1973-9478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2]]}}}